Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew D Badley

Showing results (11-20 of 156) with videos related to

Pageof 16
Sort By:
Vaccine|May 15, 2022
Could proteasome inhibition improve therapeutic vaccine response in HIV?Nathan W Cummins, Andrew D Badley
Molecular and Cellular Therapies|June 10, 2015
Making sense of how HIV kills infected CD4 T cells: implications for HIV cureNathan W Cummins, Andrew D Badley
Anti-Infective Agents in Medicinal Chemistry|August 23, 2011
The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious DiseasesBrett D Shepard, Andrew D Badley
Medicinal Chemistry (Shariqah (United Arab Emirates))|January 29, 2008
HIV protease inhibitors impact on apoptosisStacey A Rizza, Andrew D Badley
Mayo Clinic Proceedings|May 7, 2015
Can HIV Be Cured and Should We Try?Nathan W Cummins, Andrew D Badley
Mayo Clinic Proceedings|April 5, 2021
In reply-Outcomes of COVID-19 With the Mayo Clinic Model of Care and ResearchJohn C O'Horo, Andrew D Badley
Critical Reviews in Immunology|April 20, 2019
The TRAIL: TRAILshort Axis in HIV ImmunopathologyFatma Aboulnasr, Geeta Paranjape, Andrew D Badley
AIDS (London, England)|April 20, 2004
Effect on CD4 T-cell count of replacing protease inhibitors in patients with successful HIV suppression: a meta-analysisCarolyn Owen, Farouk Kazim, Andrew D Badley
Frontiers in Cellular and Infection Microbiology|March 20, 2024
Dynamic modulation of the non-canonical NF-κB signaling pathway for HIV shock and killAswath P Chandrasekar, Mark Maynes, Andrew D Badley
Mayo Clinic Proceedings|March 6, 2021
In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019Zelalem Temesgen, Saad S Kenderian, Andrew D Badley
Pageof 16

Showing results (11-20 of 156) with videos related to

Sort By:
Pageof 16
Vaccine|May 15, 2022
Could proteasome inhibition improve therapeutic vaccine response in HIV?Nathan W Cummins, Andrew D Badley
Molecular and Cellular Therapies|June 10, 2015
Making sense of how HIV kills infected CD4 T cells: implications for HIV cureNathan W Cummins, Andrew D Badley
Anti-Infective Agents in Medicinal Chemistry|August 23, 2011
The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious DiseasesBrett D Shepard, Andrew D Badley
Medicinal Chemistry (Shariqah (United Arab Emirates))|January 29, 2008
HIV protease inhibitors impact on apoptosisStacey A Rizza, Andrew D Badley
Mayo Clinic Proceedings|May 7, 2015
Can HIV Be Cured and Should We Try?Nathan W Cummins, Andrew D Badley
Mayo Clinic Proceedings|April 5, 2021
In reply-Outcomes of COVID-19 With the Mayo Clinic Model of Care and ResearchJohn C O'Horo, Andrew D Badley
Critical Reviews in Immunology|April 20, 2019
The TRAIL: TRAILshort Axis in HIV ImmunopathologyFatma Aboulnasr, Geeta Paranjape, Andrew D Badley
AIDS (London, England)|April 20, 2004
Effect on CD4 T-cell count of replacing protease inhibitors in patients with successful HIV suppression: a meta-analysisCarolyn Owen, Farouk Kazim, Andrew D Badley
Frontiers in Cellular and Infection Microbiology|March 20, 2024
Dynamic modulation of the non-canonical NF-κB signaling pathway for HIV shock and killAswath P Chandrasekar, Mark Maynes, Andrew D Badley
Mayo Clinic Proceedings|March 6, 2021
In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019Zelalem Temesgen, Saad S Kenderian, Andrew D Badley
Pageof 16